- PM Modi visit USAOnly the mirror in my washroom and phone gallery see the crazy me : Sara KhanKarnataka rain fury: Photos of flooded streets, uprooted treesCannes 2022: Deepika Padukone stuns at the French Riviera in Sabyasachi outfitRanbir Kapoor And Alia Bhatt's Wedding Pics - Sealed With A KissOscars 2022: Every Academy Award WinnerShane Warne (1969-2022): Australian cricket legend's life in picturesPhotos: What Russia's invasion of Ukraine looks like on the groundLata Mangeshkar (1929-2022): A pictorial tribute to the 'Nightingale of India'PM Modi unveils 216-feet tall Statue of Equality in Hyderabad (PHOTOS)
Freya Deshmane riding on Reinroe Adare Acrobat claimed the top spot and clinched the gold
- Salah sets Premier League record in Liverpool's draw at Newcastle
- India Open Competition in Shotgun begins in Jaipur, paving way for Nationals' qualification
- Hockey India names Amir Ali-led 20-man team for Junior Asia Cup
- Harmanpreet Singh named FIH Player of the Year, PR Sreejesh gets best goalkeeper award
- World Boxing medallist Gaurav Bidhuri to flag off 'Delhi Against Drugs' movement on Nov 17
SC directs daily dose regime for TB treatment Last Updated : 23 Jan 2017 03:49:06 PM IST (File photo)
In a big boost to the tuberculosis control programme, the Supreme Court on Monday said all new tuberculosis patients will get doses of drugs on daily basis instead of thrice a week.
Directing daily doses of fixed drugs combination treatment, Chief Justice Jagdish Singh Khehar, Justice N.V. Ramana and Justice D.Y. Chandrachud said all patients who were getting treatment under thrice-a-week-dose schedule would switch over to daily doses regimen in nine months.
The bench ordered the switch over following a PIL by Raman Kakkar, who is associated with the revised national TB control programme.
The court order came even as Additional Solicitor General Maninder Singh, appearing for the central government, told the court that the new regime could be implemented only in a phased manner.IANS For Latest Updates Please-
Join us on
Follow us on
172.31.16.186